ADMS News and Press, Adamas Pharmaceuticals Inc. From 05/30/19

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as it...

I have been following Adamas Pharmaceuticals ( ADMS ) ever since they were able to receive FDA approval for their flagship product GOCOVRI for PD dyskinesia and OFF. Since then, I have started writing for Seeking Alpha and decided to write about my Adamas journey. Most of my writing has been f...

EMERYVILLE, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Ch...

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2019 Earnings Conference Call May 09, 2019, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Gregory Went - Co-Founder, Chairman & CEO Alfred Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Parti...

Adamas Pharma (NASDAQ: ADMS ): Q1 GAAP EPS of -$1.08 beats by $0.06 . Revenue of $11.7M (+358.8% Y/Y) misses by $0.48M . Shares -6% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., May...

EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that posters regarding GOCOVRI TM (amantadine) extende...

EMERYVILLE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 first quarter financial results on Thursday, May 9, 2019, after market close. Subsequently, Adamas’ management team will host a conferenc...

With one candidate at Phase 3 of development, Trevi Therapeutics ( TRVI ) should interest IPO investors. Besides, the market will probably like the massive market opportunity. The total market for pruritus therapeutics was $11.09 billion in 2018. With that, it is not ideal that the company exp...

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...